What We'd Want to See in an Ideal Study
Designing a trial to compare retatrutide's skeletal effects against semaglutide would require a population where bone loss risk is heightened. Postmenopausal women with obesity and type 2 diabetes represent a logical cohort, given their dual burden of metabolic disease and estrogen-deficiency bone resorption. A 2021 meta-analysis estimated that women with type 2 diabetes have a 20% higher fracture risk than non-diabetic peers despite often normal or elevated bone mineral density (BMD), likely due to compromised bone quality (Vilaca 2021). The ideal protocol would randomize participants to retatrutide, semaglutide, or placebo for at least 18 months, with DXA scans at the lumbar spine and hip as the primary endpoint. Secondary measures would include trabecular bone score, a surrogate for microarchitecture, and serum turnover markers such as P1NP and CTX-1 drawn at multiple timepoints. Because retatrutide adds glucagon receptor agonism to the GIP/GLP-1 dual agonism of tirzepatide, one might hypothesize that glucagon's known effects on bone remodeling, possibly through increased osteoblast activity, could confer an advantage. Yet the hypothesis remains speculative; glucagon's skeletal role is complex and may depend on ambient insulin levels and nutritional state. A trial would also need to control for weight loss magnitude, since rapid weight reduction itself can accelerate bone loss, particularly at the hip. An ideal study would therefore include a weight-stable comparator arm or use mediation analysis to disentangle direct drug effects from those mediated by body mass changes. Finally, fracture incidence would be captured as an exploratory endpoint, though powering for this would require thousands of participants followed for years, a bar no current incretin-based trial has met.
What We Have: Existing Data on GLP-1 Agonists and Bone
The skeletal safety of GLP-1 receptor agonists has been examined in several post hoc analyses of cardiovascular outcomes trials, though none focused specifically on postmenopausal women. A 2019 analysis of the LEADER trial, which enrolled over 9,000 participants with type 2 diabetes, found no difference in fracture incidence between liraglutide and placebo over a median follow-up of 3.8 years (Mabilleau 2019). Similarly, the SUSTAIN-6 trial of semaglutide reported a fracture rate of 3.1 per 1,000 patient-years in the semaglutide arm versus 2.8 per 1,000 patient-years with placebo, a nonsignificant difference (Marso 2016). These data are reassuring but limited: fracture events were few, populations were mixed-sex, and BMD was not systematically measured. More granular evidence comes from a 2022 randomized controlled trial in 60 postmenopausal women with obesity, which found that 12 months of liraglutide treatment preserved lumbar spine BMD compared to placebo, with a between-group difference of 0.018 g/cm² (Iepsen 2022). The mechanism remains unclear but may involve weight loss-induced reductions in mechanical loading offset by direct anabolic signaling through GLP-1 receptors on osteoblasts, as suggested by rodent studies. For tirzepatide, the dual GIP/GLP-1 agonist, bone-specific data are even sparser. The SURPASS program did not include BMD endpoints, though a small substudy of 40 women from SURPASS-2 is ongoing, with results expected in 2025. Researchers conducting independent work should follow institutional protocols and ethics review where applicable. In the absence of dedicated trials, we rely on indirect evidence: GIP receptors are expressed on osteoclasts and may inhibit bone resorption, a property that could theoretically complement GLP-1's effects. However, whether this translates to clinically meaningful fracture reduction is unknown.
What's Missing: The Retatrutide Bone Gap
Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, has no published bone-specific data in humans. The phase 2 trial published in 2023 reported a 24.2% weight loss at 48 weeks in the highest dose group, but safety analyses focused on gastrointestinal events and cardiac arrhythmias, with no mention of fractures or bone biomarkers (Jastreboff 2023). This omission is not surprising given the trial's relatively short duration and younger cohort, yet it leaves a critical gap for populations at heightened fracture risk. Glucagon's skeletal effects are particularly understudied. In rodent models, intermittent glucagon administration stimulated bone formation and increased trabecular thickness, while continuous infusion had catabolic effects, suggesting that pulsatility matters (Mieczkowska 2019). Retatrutide's once-weekly dosing produces sustained receptor occupancy, which could mimic continuous exposure and potentially blunt any anabolic benefit. Moreover, the profound weight loss achieved with retatrutide, up to 17.5% more than semaglutide in indirect comparisons, raises concern about accelerated bone loss. A 2020 study of bariatric surgery patients found that each 10% reduction in body weight was associated with a 0.02 g/cm² decline in total hip BMD over two years, with women losing more than men (Stein 2020). Without dedicated trials, we cannot know whether retatrutide's triple mechanism offsets or exacerbates this risk. The ongoing phase 3 TRIUMPH program includes over 20,000 participants and will collect adverse event data, including fractures, but BMD is not a prespecified endpoint. This means the earliest opportunity for high-quality bone data may come from investigator-initiated studies or post-marketing surveillance, likely not before 2027.
How to Read the Evidence: A Clinician's Lens
When interpreting the scant literature, several principles help avoid overreach. First, fracture risk is multifactorial, and weight loss drugs can influence it through changes in body composition, fall risk, and nutritional status, not just direct bone effects. A 2021 review noted that GLP-1 agonists may improve bone quality by reducing visceral fat and systemic inflammation, but these benefits could be counteracted by declines in muscle mass and mechanical loading (Napoli 2021). Second, BMD changes are a surrogate endpoint; the correlation between BMD improvements and fracture reduction is imperfect, particularly in type 2 diabetes where bone material properties are altered. Third, sex differences matter profoundly. Most incretin trials enrolled roughly 40% women, but postmenopausal women, the group at highest fracture risk, were often underrepresented. The Tirzepatide et santé osseuse chez les femmes article explores this gap in detail, noting that female-specific RCTs are virtually nonexistent. Fourth, comparator choice shapes conclusions. Semaglutide, as a GLP-1 monoagonist, may have neutral skeletal effects, but head-to-head trials against retatrutide are needed to claim superiority. The Tirzepatide First-Line Status: ACP Obesity Guidelines 2025 piece discusses how newer agents are reshaping treatment algorithms, but
Share This Article